Improved Recombinant Adeno-Associated Viral Vector Production via Molecular Evolution of the Viral Rep Protein

In the dynamic field of gene therapy, recombinant adeno-associated viruses (rAAVs) have become leading viral vectors due to their safety, long-term expression, and wide-ranging cell and tissue tropism. With numerous FDA approvals and commercial products underscoring their potential, there is a critical need for efficient production processes to achieve high vector titers and quality. A major challenge in rAAV production is the efficient packaging of the genome into the viral capsid, with empty or partially filled capsids often representing over 90% of the produced material. To tackle this issue, we engineered the replication and packaging proteins of an AAV (Rep) to boost their functionality and improve vector titers. We subjected a complex Rep library derived from the AAV serotypes 1-13 to directed evolution in an AAV producer cell line. After each round of selection, single clones were analyzed, showing enrichment of specific hybrid Rep domains. Comparative analysis of these selected clones revealed considerable differences in their ability to package AAV2-based viral genomes, with hybrid Rep proteins achieving up to a 2.5-fold increase in packaging efficiency compared to their parental counterparts. These results suggest that optimizing <i>rep</i> gene variants through directed evolution is an effective strategy to enhance rAAV production efficiency.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2025-02-04
DOI
https://doi.org/10.3390/ijms26031319
Citations
7
Primary Topic
Virus-based gene therapy research
Type
article
Field-Weighted Citation Impact
12.72
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Improved Recombinant Adeno-Associated Viral Vector Production via Molecular Evolution of the Viral Rep Protein

Markus Haindl, Stefan Klostermann, Julia Fakhiri, Mustafa N. Yazicioglu et al.
7 citations
International Journal of Molecular Sciences
Virus-based gene therapy research
12.72
article

Improved Recombinant Adeno-Associated Viral Vector Production via Molecular Evolution of the Viral Rep Protein

Markus Haindl, Stefan Klostermann, Julia Fakhiri, Mustafa N. Yazicioglu, Florian Semmelmann, Denis Phichith, Veronika Öttl, Linda E. Franken, Stefan Linder, Philippe Ringler, Matthias E. Lauer, C. J. FRANK, Miriam Ferreiro, Stefan Seeber, Johannes Fritsch, Luisa Desiree Hilgenfeld, Thomas Steininger, Anna Sandmeir, Marie-Sofie Dürr, Fabian Konkel, Gregor Pechmann, Philip Ohland, Evelyn Hirschauer
article en
7 citations

Abstract

In the dynamic field of gene therapy, recombinant adeno-associated viruses (rAAVs) have become leading viral vectors due to their safety, long-term expression, and wide-ranging cell and tissue tropism. With numerous FDA approvals and commercial products underscoring their potential, there is a critical need for efficient production processes to achieve high vector titers and quality. A major challenge in rAAV production is the efficient packaging of the genome into the viral capsid, with empty or partially filled capsids often representing over 90% of the produced material. To tackle this issue, we engineered the replication and packaging proteins of an AAV (Rep) to boost their functionality and improve vector titers. We subjected a complex Rep library derived from the AAV serotypes 1-13 to directed evolution in an AAV producer cell line. After each round of selection, single clones were analyzed, showing enrichment of specific hybrid Rep domains. Comparative analysis of these selected clones revealed considerable differences in their ability to package AAV2-based viral genomes, with hybrid Rep proteins achieving up to a 2.5-fold increase in packaging efficiency compared to their parental counterparts. These results suggest that optimizing <i>rep</i> gene variants through directed evolution is an effective strategy to enhance rAAV production efficiency.

International Journal of Molecular SciencesVol. 26(3)
Roche (Switzerland) (CH), Roche (United States) (US), Munich University of Applied Sciences (DE), University of Basel (CH), Weihenstephan-Triesdorf University of Applied Sciences (DE), Roche Pharma AG (Germany) (DE), Spark Therapeutics (United States) (US), University of Regensburg (DE)
Openalex Percentile: Top 1%
Virus-based gene therapy research
12.72
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.